Search research articles
Contact Us
Filters
Showing results (311-320 of 322) with videos related to
Page
of 33
Sort By:
The New England Journal of Medicine
|
April 25, 2019
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
Naveen Pemmaraju, Andrew A Lane, Kendra L Sweet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2022
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia
Kendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 5, 2024
Project Confirm: Accelerated Drug Approvals for CML-Response
Kendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
The Lancet. Oncology
|
February 29, 2024
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
Naval G Daver, Pau Montesinos, Daniel J DeAngelo, et al.
Leukemia & Lymphoma
|
December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612
Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
Leukemia
|
January 3, 2022
Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts
David M Swoboda, Rashmi Kanagal-Shamanna, Andrew M Brunner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2021
Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes
David A Sallman, Amy E DeZern, Guillermo Garcia-Manero, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 6, 2020
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Michael W Deininger, Neil P Shah, Jessica K Altman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 6, 2018
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Jerald P Radich, Michael Deininger, Camille N Abboud, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 14, 2016
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017
Arnel Pallera, Jessica K Altman, Ellin Berman, et al.
Page
of 33
Search research articles
Search
Showing results (311-320 of 322) with videos related to
Sort By:
Page
of 33
The New England Journal of Medicine
|
April 25, 2019
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
Naveen Pemmaraju, Andrew A Lane, Kendra L Sweet, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2022
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia
Kendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 5, 2024
Project Confirm: Accelerated Drug Approvals for CML-Response
Kendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
The Lancet. Oncology
|
February 29, 2024
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
Naval G Daver, Pau Montesinos, Daniel J DeAngelo, et al.
Leukemia & Lymphoma
|
December 15, 2022
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612
Sarit Assouline, Laura C Michaelis, Megan Othus, et al.
Leukemia
|
January 3, 2022
Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts
David M Swoboda, Rashmi Kanagal-Shamanna, Andrew M Brunner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 15, 2021
Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes
David A Sallman, Amy E DeZern, Guillermo Garcia-Manero, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 6, 2020
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Michael W Deininger, Neil P Shah, Jessica K Altman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 6, 2018
Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Jerald P Radich, Michael Deininger, Camille N Abboud, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
December 14, 2016
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017
Arnel Pallera, Jessica K Altman, Ellin Berman, et al.
Page
of 33